Olfactory receptor OR51E2, also known as a Prostate Specific G-Protein Receptor, is highly expressed in prostate cancer but its function is not well understood. Through in silico and in vitro analyses, we identified 24 agonists and 1 antagonist for this receptor. We detected that agonist 19hydroxyandrostenedione, a product of the aromatase reaction, is endogenously produced upon receptor activation. We characterized the effects of receptor activation on metabolism using a prostate cancer cell line and demonstrated decreased intracellular anabolic signals and cell viability, induction of cell cycle arrest, and increased expression of neuronal markers. Furthermore, upregulation of neuron-specific enolase by agonist treatment was abolished in OR51E2-KO cells. The results of our study suggest that OR51E2 activation results in neuroendocrine trans-differentiation.
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Some of the newly discovered agonists are: 19-hydroxyandrostenedione (19-OH AD), a hypertensive steroid (vasopressor) secreted by the adrenal gland [52] [53] [54] , an intermediate in estrogen synthesis from testosterone 55 also found in porcine testes 56 and rat ovarian granulosa cells 57 ; acetyl-N-formyl-5-methoxykynurenamine (AFMK), a melatonin and kynurenamine metabolite previously reported to be abundant in aggressive PC 58 ; estradiol 59 ; adenosine-2,3-cyclic phosphate, a positional isomer of the second messenger 3',5'-cAMP 60 ; 8-hydroxyguanine, a marker of DNA damage; a-ketoglutaric acid, an intermediate in the citric acid cycle; urea; glycine; and palmitic acid.
Because in situ estrogen production is an important factor in prostate carcinogenesis, and since the expression of aromatase, the enzyme that synthetizes estrogens from androgens, is increased 30fold in PC, we decided to further examine the presence and production of 19-OH AD in LNCaP cells 61, 62 .
Endogenous 19-OH AD production upon OR51E2 activation with AFMK
We have developed a liquid chromatography/mass spectrometry (LC-MS/MS) assay for the measurements of 19-OH AD in the cell media. LNCaP cells were stimulated with newly discovered agonist, 250 µM AFMK, for 3 days, and the 19-OH AD was measured in the cell medium (Figure 2) .
We used CD-phenol free RPMI1640 medium (Figure 2A ) and regular RPMI1640 medium ( Figure   2B ) to estimate production of 19-OH AD. Three times more 19-OH AD was detected when cells were stimulated in CD-phenol free medium (0.83 vs. 0.27ng/mL). No 19-OH AD was detected in unstimulated cells (dotted lines in Figures 2A and 2B ).
Metabolomic Signatures of LNCaP Cells Treated with Selected OR51E2 Agonists
In addition to the newly discovered agonists 19-OH AD and AFMK, we also selected the previously identified OR51E2 agonist propionic acid (PA) for metabolomics analysis 46 . Cells were incubated with 100 nM 19-OH AD, 250 µM AFMK, and 1 mM PA for 72 h, and non-targeted metabolomics 8 analysis was performed to identify metabolites that differed significantly in the cell lysate and conditioned medium (CM). Agonist treatment resulted in pronounced intra-and extra-cellular changes in metabolomic signatures, as seen in heat maps (Figures S5 and S6 , respectively).
Differentially expressed features/metabolites identified in each group using the t-test (P < 0.05) and fold change (2-fold or greater) are presented in Figures S5-S10 and Tables S5-S10.
The top 15 differentially expressed extracellular metabolites are presented in Figures 3A, 3B , and 3C. All 3 agonists also produced robust intracellular decreases in amino acids, especially serine and threonine, and also 2 glycolytic intermediates: glucose-6-P and fructose-6-P (Figure 3D, 3E and 3F ).
Furthermore, agonist treatment resulted in decreases in both methionine and glycine levels. In addition to decreased lactic acid, significant decreases were noted in fumaric, malic, and succinic acids, all intermediates of the TCA. Interestingly, we detected an increased level of phosphoenolpyruvate (PEP) in all agonist-treated samples (fold change analysis, Figures S7B, S8B and S9B). We also observed decreased levels of myoinositol, inosine, adenosine, asparagine, aspartate, and guanosine, which have been previously reported as being depleted in metastatic PC tissue 49 , indicating that activation of OR51E2 by agonists in LNCaP cells produces metabolic signatures similar to those observed in human metastatic tissues. Agonist treatment also reduced levels of intracellular urea and spermine/spermidine, in accordance with recently reported data showing reduced spermine during malignant transformation 63 . Accordingly, we also detected decreased intracellular levels of ornithine, a precursor of polyamines.
Fold change analysis of the CM revealed significantly increased glutamine (25-, 11-, and 51-fold, for 19-OH AD, AFMK, and PA, respectively), indicating that agonist-treated cells do not have an increased demand for glutamine as highly proliferating cancer cells usually do (Figures S10B, S11B, and S12B). Thus, these results argue for a non-or a low-proliferative phenotype. Decreased levels of docosanoic and decanoic acid and increased levels of asparagine were also prominent in the CM in 9 all 3 treatments ( Figure 4G) . The pathways most affected, as identified by MetaboAnalyst, were the serine, threonine, and glycine; alanine, aspartate, and glutamine; ketogenesis; arginine and proline; and beta-alanine metabolic pathways (Figure 4F ).
Time-dependent Modulation of Cellular Proliferation
Our metabolomics results indicated reduced capacity for anabolic reactions in LNCaP cells following receptor activation, which prompted us to further analyze the effects of OR51E2 agonists on cellular proliferation. Moreover, because melatonin reduces cell proliferation, we examined whether AFMK, a melatonin metabolite, also reduces or inhibits cell proliferation 64 . LNCaP cells were stimulated with various concentrations of 19-OH AD and AFMK for 4 days and analyzed every 24 hours using an ATP viability assay. At day 4, both agonists significantly decreased the number of viable cells when compared to the control, non-stimulated cells (Figure 5A) . This effect was dependent on cell seeding density; at higher plating densities (40% to 50%), the effect was not observed.
Cell Cycle Arrest
Next, we determined if the decrease in cell viability during agonist stimulation is attributable to increased apoptosis or cell-cycle arrest. Cells were treated with various concentrations of agonists for 3 and 7 days. Both agonists increased the fraction of cells in the G0/G1 phase and decreased the number of apoptotic cells (Figure 5B ). Our results are in agreement with previous reports that the majority of cells with a neuroendocrine-like phenotype show signs of resistance to apoptosis 65 .
Neuroendocrine Markers
To assess the effect of selected OR51E2 agonists on NEtD, we analyzed transcript levels after 3 and 12 days of stimulation of the following neuroendocrine, epithelial, and receptor genes: NSE; αmethylacyl-CoA racemase (AMACR); keratins 5, 8, and 18; voltage-gated Ca channel a1H (Cav3.2); androgen receptor (AR); and OR51E2 receptor. NSE was used to specifically identify NEtD status, 10 and although LNCaP (being a cell line established from lymph-node metastatasis) cells already express low levels of NSE, treatment with OR51E2 agonists significantly increase levels of the NSE transcript (Figures 5C, 5D , and 5E). These results correlate well with the increased intracellular level of PEP detected in the metabolomic analysis ( Figures S7B, S8B and S9B) , since the glycolytic enzyme enolase catalyzes PEP synthesis. α-AMACR is an enzyme essential for isomerization of branched-chained fatty acids and is present at very low levels in healthy prostate and increased in PC and NE-like cells 66 . Since NE-like tumor cells express AMACR, we investigated whether activation of OR51E2 also increased AMACR levels. Indeed, AMACR levels were significantly increased after 3 and 12 days of agonist stimulation (Figures 5C, 5D , and 5E).
Furthermore, 19-OH AD decreased the AR transcript after 12 days, and although AFMK also showed a similar trend, it did not reach statistical significance (Figure 5D ). Normal basal prostate epithelial cells are positive for K5, and expression of K5 is also associated with the epithelial-to-mesenchymal transition during tumor progression and metastasis 67 . K5 and K8 were not detected in the agoniststimulated cells (data not shown). A significant decrease in K18, a luminal secretory marker, was found after 12 days of stimulation with 100 nM 19-OH AD (Figure 5D ). Although Ca +2 entry through the voltage-gated calcium channel a1H (Cav3.2) was previously reported to be involved in NEtD of LNCaP cells when cultured in steroid-free conditions, we did not detect changes in its transcript levels (data not shown) 68 .
OR51E2 Knock-out Confirms NE-like Phenotype Upon Receptor Activation
To confirm receptor involvement in the agonist-mediated increase of NSE, OR51E2 was deleted using a CRISPR-Cas9 method (Figure 5F ). We designed 3 gRNAs to target Cas9 to the OR51E2gene and generated a lentiviral sgRNA-Cas9 vector to deliver gRNA into cells. The efficiency of each gRNA was measured, and we observed that by using sgRNA #1, OR51E2 was abrogated in 80% of cells . These OR51E2-knockout cells were exposed to 1 µM 19-OH AD for 3 days and analyzed for 11 the presence of specific markers (Figures 5G and 5H) . A statistically significant decrease of NSE in OR51E2-knockout cells in comparison with control cells was observed (from 0.579 ± 0.043 in control to 0.377 ± 0.04, P < 0.05, n = 4 biological replicates, Figure 5G) , confirming that increased NSE during stimulation with agonists is at least partially a receptor-mediated phenomenon (Figures 5C   and 5D ).
DISCUSSION
As the number of ectopic olfactory receptors associated with diverse pathological states continues to increase 15, 17 , the implications and significance of these receptors will be greatly enhanced by receptor "deorphanization" (i.e., defining the ligands). Previously, we successfully identified novel ligands for mouse OR using a similar in silico approach with VLS 69 . Here, we present a highly successful approach of combining in silico and in vitro analyses to identify novel biologically relevant ligands for the human ectopic OR OR51E2. This method can be used to elucidate ligand specificities of other ectopic ORs. Once identified, these new ligands can help define the role and function of ORs in cancer and other diseases.
Among the newly discovered metabolites identified as OR51E2 agonists, several were previously reported to be associated with PC, including bradykinin, kojibiose, glycylglycine, N-acetylglutamic acid, and D-alanyl-D-alanine 49 . Thus, our results indicate that these metabolites are likely endogenous agonists. New agonists with known biological roles were also discovered: epitestosterone, known to be a major metabolite of androstenedione and testosterone 70 ; and androstanedione (also known as 5α-androstane-3,17-dione), an intermediate in steroid synthesis 71 .
In addition to these agonists, we also identified a previously under-reported metabolite of the complex steroid biosynthetic network, 19-hydroxyandrost-4-ene-3,17-dione (19-OH AD) 55, 72, 73 . 19-OH AD is produced by aromatase P450 (CYP19A1), which catalyzes the irreversible aromatization of the 12 androgens androst-4-ene-3,17-dione and testosterone and their consequent conversion to estrogens (http://www.brenda-enzymes.org/enzyme.php?ecno=1. 14.14.14) . We detected this testosterone metabolite in agonist-stimulated prostate cancer cells. These results demonstrate that 19-OH AD is actively produced by cancer cells when the OR51E2 receptor is activated. Thus, we demonstrate that 19-OH AD is an endogenous agonist produced by activation of OR51E2 in prostate cancer cells.
Aromatase is increased 30-fold in metastatic PC 62 , and aromatase-knockout mice have a reduced incidence of PC following exposure to testosterone and estrogen, indicating that aromatase metabolites, mainly 19-OH AD and estradiol, are likely involved in prostate carcinogenesis. Results from our study demonstrate that 19-OH AD is a potent OR51E2 agonist (EC 50 = 1.5 -10 M) and support the notion that increased in situ estrogen production via 19-OH AD is an important factor in PC 61 .
AFMK is a metabolite of melatonin 74 . Previous studies demonstrated that melatonin reduces proliferation of LNCaP cells, leading to NEtD, and the phenotype was not reversed by melatonin receptor antagonists, suggesting that additional receptors may be mediating this process 64, 75 . Our results demonstrate that OR51E2 is a receptor for AFMK, a melatonin metabolite, and although its EC 50 is in the µM range, much higher than reported blood concentrations (<65 pM) 76 , the local tissue concentration may reach µM and mM levels as has been recently shown for keratinocytes 74 . An additional source of AFMK might be a tryptophan metabolic pathway 77 . Tumors produce high levels of tryptophan and kynurenic acid metabolites 78 . Significant amplification of tryptophan-2,3dioxygenase (EC 1.13.11.11) TDO2, which catalyzes the oxidation of L-tryptophan to N-formyl-Lkynurenamine, was observed in NEPC and PC 79, 80 . Thus, in more advanced stages of PC, AFMK production may be increased via this tryptophan metabolic pathway. Recently, this pathway was shown to regulate the immunosuppressive microenvironment of various tumors 81 . 13 We also identified bradykinin as an agonist for OR51E2. In general, kinins are released during the inflammatory reaction and they are involved in angiogenesis and tumorigenesis 82, 83 . Our results indicate that the activation of OR51E2 by bradykinin can also happen in the early stages of PC, when the inflammatory milieu is predominant. Prostatic secretions of PC patients have elevated levels of human kallikrein 2 84 , which produces bradykinin and thus stimulates proliferation of androgenindependent PC cells in later stages of PC 85 .
The OR51E2 antagonist 13-cis RA is an endogenous component of human serum, and many of its actions can be explained by isomerization to all-trans RA and 9-cis RA, which both act via retinoid receptors. However, since 13-cis RA does not have potent gene regulatory activity, additional pathways via membrane receptors have been proposed to explain its pharmacological and antiinflammatory actions 86 . Our results demonstrate that 13-cis RA acts via the OR51E2 receptor when expressed heterologously.
OR51E2 receptor activation by 19-OH AD, AFMK, and PA induced pronounced metabolic reprograming of LNCaP cells, with the most significant changes being decreased intracellular serine and threonine levels. Because metabolism of these amino acids includes one-carbon metabolism, which provides cofactors for biosynthetic reactions in highly proliferating cells, intracellular depletion may indicate a general decrease in anabolic reactions 87 . Furthermore, an intracellular decrease in aspartate, which is normally required for protein, purine, and pyrimidine synthesis, and an increase in the CM indicate that agonist-activated LNCaP cells are not preparing for proliferation. We also detected decreased intermediates of glycolysis (glucose-6-phosphate and fructose-6-phosphate) in activated cells. Agonist treatment decreased intracellular lactate, suggesting a slower rate of glycolysis. An intriguing result was the increased intracellular level of phosphoenolpyruvate (PEP).
We also found increased NSE transcription for the glycolytic enzyme enolase, which catalyzes the formation of PEP, indicating predominance of the PEP-forming reaction. 14 
NSE
is not only a marker of neuronal differentiation and maturation characteristic of neurons and neuroendocrine cells 88 , but it also has an important role in synaptogenesis 89 and is reported to be stable in the high-chloride environment characteristic of neurons, in which it reaches a concentration of 2% to 3% of the soluble protein 90 . Taken together, these results indicate that receptor activation results in a neuronal-like phenotype of LNCaP cells.
Cystine was increased in the medium after 19-OH AD and AFMK treatment (Tables S12 and S13). In healthy cells, cystine is transported into cells and reduced to cysteine, which can then be utilized for synthesis of gluthatione, a protective antioxidant. As a consequence of rapid cell growth during tumorigenesis, the production of reactive oxygen species increases, providing a proliferative signal for glutamine to enter the cell and, after deamidation, condense with cysteine to form a precursor of glutathione. However, in our experiments, the medium, but not the cells, showed increased levels of glutamine and cysteine, indicating a reduction in protective oxidative and proliferative signals in agonist-stimulated cells. The alanine/aspartate/glutamine pathway is the most affected biochemical pathway during NEtD of LNCaP cells induced by steroid-reduced medium, which corroborates our results 91 (Figure 4F) . In cancer-associated fibroblasts, asparagine and aspartate are involved in glutamine synthesis 92 , and our experiments showed decreased intracellular levels of these amino acids, suggesting increased use for intracellular synthesis of glutamine. These results might also indicate a decreased cellular influx of asparagine, since it is abundant in CM. Flux studies will be necessary to determine the exact relationship between glutamine synthesis and transport in PC cells upon receptor activation.
To explain the role of OR51E2 in PC, we propose the following model: agonist stimulation generates new cells through asymmetric division and gradually increases the subpopulation of terminally differentiated cells expressing neuroendocrine markers (see graphical abstract). 15 NE-like cells from PC are characterized by increased expression of NSE and AMACR and decreased expression of K18 and AR 34, 93, 94 . Increased expression of NSE and AMARC and decreased expression of AR and K18 following 19-OH AD and AFMK treatment demonstrate that these OR51E2 agonists induce a neuroendocrine phenotype. We confirmed that this effect is receptor-mediated, as treatment of OR51E2-knockout LNCaP cells significantly reduced the NSE and AMACR transcript levels.
Cell proliferation and differentiation have an inverse relationship, and terminal differentiation coincides with proliferation arrest and exit from the division cycle 95 . Our results demonstrate that agonist treatment during the first 3 days induces cell proliferation at a rate similar to control cells, but after 4 days the viability of these cells, as measured by ATP content, was significantly reduced. Our results also demonstrate that receptor activation results in a new subpopulation of cells that undergoes G0/G1 cell cycle arrest and has decreased DNA synthesis, which is concordant with the results from our metabolomics analysis. Cellular senescence is an irreversible growth arrest, and senescent cells actively suppress apoptosis 96 . We found that agonist treatment decreases the fraction of apoptotic cells, indicating that growth arrest likely induces cellular senescence. Future studies are needed to confirm the irreversibility of this process.
Furthermore, recent whole-exome sequencing of NEPC and CRPC showed an overlap in genomic alterations, and in both demonstrated increased amplification of the OR51E2 gene, supporting our hypothesis that this receptor contributes to the NE-phenotype of PC 79, 80 .
Prostatic adenocarcinomas typically contain foci of non-proliferating NE-like cells that increase in number as cancer progresses 97 . Although these cells are non-mitotic, proliferating carcinoma cells have been found in their proximity, suggesting that the non-proliferating NE-like cells likely provide paracrine stimuli for growth of the surrounding carcinoma cells 98, 99 . Our results demonstrate that 16 activation of OR51E2 by newly-discovered PC-relevant agonists induces and/or facilitates cellular transformation, resulting in NEtD, a characteristic phenotype of CRCP. This indicates that activation of OR51E2 in PC might contribute to development of non-proliferating foci. Our data demonstrate that activation of OR51E2 results in NEtD and establish this GPCR as a novel and therapeutic target for NEPC and CRPC. 
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Conceptualization
Virtual Library Screening
The library used for VLS was selected from the HMDB (www.HMDB.ca) and consisted of metabolites detected in human blood, tissue, urine, and saliva. VLS was performed with the ICM software as described previously 69 The mfScore function is a knowledge-based potential derived from the frequencies of occurrence of various atom pairs within the experimental ligand/receptor complex structures deposited in the Protein Data Bank (PDB) 106 . It represents a measure of statistical probability of interaction between the ligand and receptor. Our previous results indicate that both scoring functions were equally successful in predicting ligands 69 . The top 50 hits from each scoring list are presented in Tables S1 and S2.
Cell Culture
randomly selects a conformation in the internal coordinate space and makes a new random position independent of the previous one. From the complete VLS hit list presented in Table S1 , two top 20 lists were generated, first by sorting compounds for best docking score (score -24.49) and second by sorting compounds for best mfscore (mfscore -109.77). The score in ICM software is based on the empirical function of predicted physical interaction terms as described in the following formula:
This predicted score (kcal/mol) is calculated as the weighted (α1-α5) sum of ligand-target van der Waals interactions and internal force field energy of the ligand ( E IntFF ), free energy changes due to conformational energy loss upon ligand binding (T S Tor ), hydrogen bonding interactions ( E HBond ), hydrogen bond donor-acceptor desolvation energy ( E HBDesol ), solvation electrostatic energy upon ligand binding ( E SolE1 ), hydrophobic free energy gain ( E HPhob )and a size correction term proportional to the number of ligand atoms (Q Size ), as described in detail in the Neves et al. paper [20] . On the contrary, mfscore in ICM software is a potential of mean force score and provides an independent score of the strength of ligand-receptor interaction. It is a measure of statistical probability of interaction between the ligand and the receptor. It examines interatomic distances of the docked interaction, and compares that to existing interactions available in PDB [21] . The mean force Score (mfScore) is calculated following methodology of Muegge &Martin [22] . It is a knowledge-based potential derived from frequencies of occurrence of various atom pairs at different distances within experimental ligand/receptor complex 26 Prostate cancer LNCaP-FGC cells derived from lymph node metastatic site (passage 30-32) were obtained from the American Type Culture Collection (ATCC). Cells were maintained at 37°C in RPMI-1640 medium (Sigma R8758) enriched with 0.5% glucose (45%, Sigma G8769), 1% 1 M HEPES (Gibco-Thermo 15630), 1% 100 mM Na-pyruvate (Gibco-Thermo 11360), 10% FBS (HyClone, SH30071.03), 100 U/mL penicillin, and 0.1 mg/mL streptomycin. At 4 to 5 days after seeding, cells were 70% to 80% confluent and the stimulus was applied at the indicated concentration for the indicated time. The medium was replaced every fourth day.
Luciferase Assay
Briefly, the OR51E2 plasmid was transfected into HANA3A cells along with a CREB-dependent luciferase (firefly) and a constitutively active luciferase (Renilla) 46 . Upon ligand binding, an increase in cAMP drives the expression of firefly luciferase and increases the signal. To control for variation in cell number and transfection efficiency, the luciferase signal was normalized to the activity of the Renilla luciferase in the same cells. All stock solutions of chemicals were prepared either in dimethylsulfoxide (DMSO) or ethanol. Final dilutions were made in M10d medium. M10d is MEM medium enriched with 5% dialyzed FBS serum, which is devoid of small molecular weight compounds (<10,000 Da), since OR51E2-transfected cells gave a high luciferase signal in the CD293 medium (Gibco 11913-019, supplemented with 30 µM CuCl 2 and 2 µM L-glutamine) even in the absence of chemical stimulation and when compared to the basal activity of the control OR2W1 receptorexpressing cells (data not shown). All compounds that did not show agonist activity in M10d were later diluted in CD293 medium and tested for antagonist activity. The rest of the protocol was performed as previously published 46 . Cells were exposed to candidate ligands for 3.5 hours at various concentrations. For each compound that showed a response >2 SD of the baseline response (no chemical applied), the EC 50 or IC 50 was determined from a sigmoid dose-response curve using a 27 Graph-Pad Prism (Graph-Pad Prism Software, San Diego, USA). Data were fitted to the equation: Y = Bottom + (Top-Bottom)/(1+10^((LogIC50-X) *HillSlope)).
19-OH AD measurements using LC/MS
LNCaP cells were first grown in T-75 flasks until just fully confluent. Cells were then split into 6 T-25 flasks Cells were exposed to 250 µM AFMK, or to the medium only, for 3 days. We used phenol-red free RPMI 1640 with 10% CD-serum (Hyclone, SH30068) or RPMI 1640 with 10% FBS, as described in cell culture protocol. After 3 days, medium was collected and frozen at - 
Metabolomics GC-MS Analysis
LNCaP cells were first grown in T-75 flasks until just fully confluent. Cells were then split into 6 T-25 flasks and exposed to agonists the following day: 250 µM AFMK, 100 nM 19-OH AD, or 1 mM 28 propionic acid (PA), with 6 biological replicates in each group. After agonist treatment for 3 days, CM was removed and banked at -80°C, and the cells were rinsed with 10 mL ice-cold PBS. Next, 3 mL of ice-cold 0.9% NaCl were added, and cells were scraped off of the plates and transferred to 5-mL tubes that were previously cleaned with acetonitrile. Each flask was rinsed with an additional 2 mL of ice-cold 0.9% NaCl, and the cell suspensions were transferred to the 5-mL tubes and centrifuged at 1000 rpm for 5 min at 4°C. Supernatant was removed, and 200 µL of ice-cold dH 2 0 with 0.6% formic acid were added to the cell pellets. Then, 20 µL of resuspended cell pellets were separated for protein measurements (Qubit Protein Assay kit, Cat. # Q33211, Thermo Fisher Scientific), and 180 µL of acetonitrile were added to the remaining pellet. Prepared cell lysates were maintained at -80°C until metabolomics analysis. Metabolites were identified using our retention time-referenced spectral library [110] [111] [112] , which is based in part on that of Kind et al. 113 . Reported data are log 2 transforms of the areas of deconvoluted peaks.
Data were normalized to the protein content in each sample. MetaboAnalyst 3.0 was used for statistical analysis 114 . Briefly, peak intensity data were presented in columns and log 2 -normalized.
We used unpaired analysis, and data were auto-scaled (mean-centered and divided by the standard 29 deviation of each variable). For pathway analysis, we used a Globaltest pathway-enrichment analysis algorithm 115 in MetaboAnalyst 3.0.
RT-PCR Analysis
LNCaP cells were grown in T-75 flasks until fully confluent. A split ratio of 1:6 was used to subculture the cells in T-25 flasks for 24 to 48 hours before stimulation. Stimulation with agonists lasted 3 or 12 days. Medium was changed every 4 days in the 12-day experiment. Total RNA was extracted using Trizol reagent (Invitrogen) and cleaned using the RNeasy kit (Qiagen) following the manufacturer's protocol. Integrity of total RNA was confirmed by agarose gel electrophoresis. cDNA was generated by reverse transcription using SuperScript II Reverse Transcriptase (Invitrogen). Primers for the following genes were designed with the Primer 3.0 program: OR51E2, NSE-neuron-specific enolase, AMACR-α-methylacyl-CoA racemase, a1H T-type calcium channel (Cav3.2), AR-androgen receptor, GAPDH, keratin 5, keratin 8, and keratin 18 ( Table S3 ). PCR amplification was performed with HotStart Taq Polymerase (Qiagen) using the following protocol: 95°C for 15 min followed by 30 cycles at the following times and temperatures: 95°C for 15 s, 55°C for 15 s, and 72°C for 30 s. Final annealing was done at 72°C for 5 min. Expression levels of the test genes were normalized to GAPDH.
Cell Proliferation Assay
Cells were plated in five 96-well plates (100 µL cell suspension per well) and after overnight attachment when cells were 15% to 20% confluent, cells were stimulated with increasing concentrations of selected agonists. Cell growth and viability was estimated each day for the next 4 days by using Cell Titer-Glo Luminescent Cell Viability Assay (Promega, Cat. No. G7570) according to the manufacturer's instructions. 30 
Cell Cycle Analysis
LNCaP cells were plated in 100-mm Petri dishes. After overnight attachment, when cells were 40% to 50% confluent, cells were stimulated once with 100 nM 19-OH AD and 250 µM AFMK for the next 4 days. Cells incubated in the regular RPMI-1640 medium served as controls. After treatment, cells were trypsinized with 0.05% trypsin-EDTA (Gibco) and fixed with 70% ethanol in PBS for 15 min at 
LNCaP OR51E2 Knockout Cell Lines
To generate CRISPR/Cas9-mediated knockout LNCaP cells, we cloned sgRNAs targeting exon 2 of 
Quantification and Statistical Analysis
All results are expressed as means ± SEM. Computations assumed that all groups were samples from populations with the same scatter. The investigators involved in this study were not completely blinded during sample collection or data analysis. Significance was determined by (multiple) twotailed unpaired t-test using Prism 7 software. A P value of 0.05 was considered significant. 
Reagent and Resource
